Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 10/20 | 0.56 |
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30481206 | 1.00 | PTK2 (0.65) | PTK2L3MBTL1TDP1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL26987783 | 0.98 | PTK2 (0.63) | PTK2L3MBTL1TDP1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL30722380 | 0.98 | PTK2 (0.63) | PTK2L3MBTL1TDP1RAB9ANPC1 | |
| SCHEMBL24654650 | 0.86 | L3MBTL1 (0.78) | PTK2L3MBTL1TDP1RAB9ANPC1 | |
| SCHEMBL29538166 | 0.84 | NPSR1 (0.65) | PTK2L3MBTL1TDP1RAB9ANPC1 | |
| SCHEMBL4687835 | 0.84 | NPSR1 (0.65) | PTK2L3MBTL1TDP1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL30054295 | 0.83 | NPSR1 (0.64) | PTK2L3MBTL1TDP1RAB9ANPC1 | |
| Hydrochloric Acid SCHEMBL616304 | 0.83 | NPSR1 (0.64) | PTK2L3MBTL1TDP1RAB9ANPC1 | |
| SCHEMBL10015596 | 0.83 | PTK2 (0.74) | PTK2L3MBTL1TDP1RAB9ANPC1 | |
| SCHEMBL26274442 | 0.82 | L3MBTL1 (0.72) | PTK2L3MBTL1TDP1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631932-A1 | PREPARATION METHOD FOR EDOXABAN AND INTERMEDIATE THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | claimed |
| EP-4631932-A1 | PREPARATION METHOD FOR EDOXABAN AND INTERMEDIATE THEREOF | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| CN-118146145-A | Preparation method of ideoxaban and intermediate thereof | 浙江华海药业股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2024009206-A1 | A PROCESS FOR THE PREPARATION OF EDOXABAN AND ITS INTERMEDIATES | AMI LIFESCIENCES PRIVATE LIMITED (IN) | 2024-01-11 | — | — | WO | disclosed |
| CN-116410128-A | Method for preparing tosylate Ai Duosha class intermediate by one-pot method | 江苏宇锐医药科技有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2020-11-12 | — | — | US | disclosed |
| WO-2019115586-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | Phenex Discovery Verwaltungs-GmbH (DE) | 2019-06-20 | — | — | WO | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| CN-1826333-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-08-30 | — | — | CN | disclosed |
| CN-1751025-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-03-22 | — | — | CN | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352931-A1 | OXALAMIDES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | PTK2 4495/4885L3MBTL1 4472/4885TDP1 1624/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | PTK2 3650/4885L3MBTL1 985/4885TDP1 2062/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | PTK2 3877/4885L3MBTL1 385/4885TDP1 922/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | PTK2 3877/4885L3MBTL1 385/4885TDP1 922/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | PTK2 3877/4885L3MBTL1 385/4885TDP1 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.